To assess the sensitivity of the RAD51-FFPE test to identify breast tumors with genomic-HRD, i.e., (epi)genetic defects in HR-related genes, we performed NGS analysis applying an HRD gene panel comprising 18 genes and applied MS-MLPA to identify BRCA1 promotor hypermethylation (Materials and Methods Sect. "Genetic and epigenetic analyses"). The gene discussed is RAD51; the disease is breast neoplasm.